Department of General Surgery, the First Affiliated Hospital of Anhui Medical University, 218 Jixi Road, Hefei, China.
World J Surg Oncol. 2022 May 27;20(1):167. doi: 10.1186/s12957-022-02631-0.
The present study comparatively analyzed short-term clinical effectiveness and long-term follow-up endpoints associated with robotic-assisted sphincter-preserving surgery (RAS) and laparoscopic-assisted sphincter-preserving surgery (LAS) when used to treat low rectal cancer.
Within such a single-center retrospective cohort analysis, low rectal cancer patients that underwent RAS (n=200) or LAS (n=486) between January 2015 and beginning of July 2018 were enrolled.
The mean operative durations in the RAS and LAS cohorts were 249±64 min and 203±47 min, respectively (P<0.001). Temporary ileostomy rates in the RAS and LAS cohorts were 64.5% and 51.6% (P = 0.002). In addition, major variations across such cohorts regarding catheter removal timing, time to liquid intake, time to first leaving bed, and length of hospitalization (all P<0.001). This distal resection margin distance within the RAS cohort was diminished in comparison to LAS cohort (P=0.004). For patients within the LAS cohort, the time required to recover from reduced urinary/female sexual function was > 6 months post-surgery (P<0.0001), whereas within the RAS cohort this interval was 3 months (P<0.0001). At 6 months post-surgery, male sexual function within RAS cohort was improved in comparison to LAS cohort (P<0.001). At 6 months post-surgery, Wexner scores revealed similar results (P<0.001). No major variations within overall or disease-free survival were identified across these cohorts at 3 or 5 years post-surgery.
Robotic sphincter-preserving surgery is a safe and effective surgical technique in low rectal patients in terms of postoperative oncological safety and long-term endpoints. And the RAS strategy provides certain additional benefits with respect to short-term urogenital/anorectal functional recovery in treated patients compared to LAS.
本研究比较分析了机器人辅助保肛手术(RAS)和腹腔镜辅助保肛手术(LAS)治疗低位直肠癌的短期临床疗效和长期随访终点。
在这项单中心回顾性队列分析中,纳入了 2015 年 1 月至 2018 年 7 月初接受 RAS(n=200)或 LAS(n=486)治疗的低位直肠癌患者。
RAS 组和 LAS 组的平均手术时间分别为 249±64 分钟和 203±47 分钟(P<0.001)。RAS 组和 LAS 组的暂时性肠造口术率分别为 64.5%和 51.6%(P=0.002)。此外,两组在导管拔除时间、液体摄入时间、首次离床时间和住院时间等方面存在明显差异(均 P<0.001)。RAS 组的远端切除边缘距离小于 LAS 组(P=0.004)。LAS 组患者术后恢复尿功能/女性性功能所需时间>6 个月(P<0.0001),而 RAS 组为 3 个月(P<0.0001)。术后 6 个月,RAS 组男性性功能优于 LAS 组(P<0.001)。术后 6 个月,Wexner 评分也显示出类似的结果(P<0.001)。术后 3 年和 5 年,两组在总生存率和无病生存率方面无明显差异。
机器人保肛手术在术后肿瘤学安全性和长期随访终点方面是一种安全有效的手术技术。与 LAS 相比,RAS 策略在治疗患者的短期泌尿/肛肠功能恢复方面提供了一定的额外益处。